Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.3%

1 terminated out of 44 trials

Success Rate

88.9%

+2.4% vs benchmark

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed with results

Key Signals

1 with results89% success

Data Visualizations

Phase Distribution

34Total
Not Applicable (6)
Early P 1 (9)
P 1 (11)
P 2 (6)
P 3 (1)
P 4 (1)

Trial Status

Recruiting18
Completed8
Not Yet Recruiting7
Unknown5
Active Not Recruiting3
Suspended1

Trial Success Rate

88.9%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (44)

Showing 20 of 20 trials
NCT00055055Completed

Study of Families With Twins or Siblings Discordant for Rheumatic Disorders

NCT05879419Phase 4Active Not Recruiting

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases

NCT07295847Phase 1Recruiting

A Study of AZD0120 in Autoimmune Diseases

NCT06916806Phase 1Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.

NCT05200702Not ApplicableCompleted

Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders

NCT07526350Early Phase 1Recruiting

MTS109 in Patients With Refractory Autoimmune Diseases

NCT05199246Not ApplicableCompleted

Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders

NCT06733935Phase 1Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT06375993Phase 1Enrolling By Invitation

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

NCT06548607Early Phase 1Recruiting

Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases

NCT06152172Phase 1Active Not RecruitingPrimary

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

NCT00341679Completed

Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases

NCT06665256Phase 2RecruitingPrimary

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

NCT06549296Early Phase 1Suspended

Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

NCT07333196Not Yet Recruiting

Tongji NADs Cohort

NCT06479863Early Phase 1Recruiting

Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

NCT06255028Phase 1Active Not Recruiting

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT07284797Phase 1Not Yet Recruiting

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)

NCT07077304Not Yet Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

NCT07022197Phase 1Recruiting

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Scroll to load more

Research Network

Activity Timeline